MUC1 and esophageal cancer: The engineered MUC1 targeted CAR-T cells activated the JAK-STAT pathway, secreted higher level of cytokines, showed superior proliferative capacity and persistence, and mediated greater antitumor activity both in subcutaneous xenograft tumors and a PDX mouse model of esophageal cancer (30).